Gilead said its product sales for Q3 2026 rose 13% from a year earlier to $8.3 billion, and that excluding Veklury, they rose 16% to $8.2 billion. The company cited higher sales of HIV products, Trodelvy and Livdelzi as the main drivers.

1. 01

   Gilead said its product sales for Q3 2026 rose 13% from a year earlier to $8.3 billion, and that excluding Veklury, they rose 16% to $8.2 billion. The company cited higher sales of HIV products, Trodelvy and Livdelzi as the main drivers.

2. 02

   The company said its diluted EPS for Q3 was $1.94, compared with $2.43 a year earlier, and that its non-GAAP diluted EPS was $2.55, compared with $2.47 a year earlier. It cited net losses on equity securities, higher operating expenses and higher income tax expense as factors behind the GAAP EPS decline.

3. 03

   Gilead said that as of September 30, 2026, it had $6.4 billion in cash, cash equivalents and marketable debt securities, down from $10.6 billion as of December 31, 2025. It also said its operating cash flow for Q3 was $5.0 billion.

4. 04

   Gilead said it expects full-year 2026 product sales of $31,000 million to $31,300 million. The company stated that its outlook as of August 4, 2026 was previously $30,100 million to $30,400 million.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.